Montana legislation · 2025 Regular Session
Montana HB399: Revise prior authorization laws
Status: Signed into law, April 17, 2025
What the bill says
An act revising prior authorization laws; prohibiting prior authorization for oral and inhaled generic prescription drugs; prohibiting prior authorization for inhaled prescription drugs for asthma, chronic obstructive pulmonary disease, or chronic lung disease; prohibiting prior authorization for insulin; requiring insurers to provide a list of reasonable therapeutic alternatives if the insurer makes an adverse determination for a prescription drug; and amending section 33-32-221, mca.
From the engrossed text:
AN ACT REVISING PRIOR AUTHORIZATION LAWS; PROHIBITING PRIOR AUTHORIZATION FOR ORAL AND INHALED GENERIC PRESCRIPTION DRUGS; PROHIBITING PRIOR AUTHORIZATION FOR INHALED PRESCRIPTION DRUGS FOR ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, OR CHRONIC LUNG DISEASE; PROHIBITING PRIOR AUTHORIZATION FOR INSULIN; REQUIRING INSURERS TO PROVIDE A LIST OF REASONABLE THERAPEUTIC ALTERNATIVES IF THE INSURER MAKES AN ADVERSE DETERMINATION FOR A PRESCRIPTION DRUG; AND AMENDING SECTION 33-32-221, MCA. Section 1. Section 33-32-221, MCA, is amended to read: "33-32-221. Prior authorization requirements. (1) A health insurance issuer or an entity that it contracts with to perform prior authorization on its behalf may not perform prior authorization on benefits for: (a) any generic prescription drug that is not included in subsections (1)(d) through (1)(g) and that is not listed within any of the schedules of controlled substances found at 21 CFR 1308.11 through 21 CFR 1308.15 or the schedules of controlled substances found in Title 50, chapter 32, after a covered person has been prescribed the covered drug at the same quantity without interruption for 6 months; (b) any prescription drug or drugs, generic or brand name, on the grounds of therapeutic duplication for the same drug if the covered person has already been subject to prior authorization on the grounds of therapeutic duplication for the same dosage of the prescription drug or drugs and coverage …
Sponsors
- Karlen, Jonathan (D, 98) · primary sponsor
- Curdy, Willis (D, 49)
Latest actions
- : Chapter Number Assigned
- : (H) Signed by Governor
- : (H) Transmitted to Governor
- : (S) Signed by President
- : (H) Signed by Speaker
- : (H) Returned from Enrolling
- : (H) Sent to Enrolling
- : (S) 3rd Reading
- : (S) Scheduled for 3rd Reading
- : (S) 2nd Reading
Votes
- Do Concur (April 3, 2025): 38 yea, 12 nay, passed
- Do Concur (April 2, 2025): 43 yea, 7 nay, passed
- Do Pass (March 4, 2025): 86 yea, 13 nay, passed
- Do Pass (March 3, 2025): 91 yea, 6 nay, passed
Subjects: Insurance, Health Care Services
Common questions
- What is HB399?
- HB399 is a bill in the Montana Legislature (2025 Regular Session): Revise prior authorization laws.
- What does HB399 do?
- In its own words: An act revising prior authorization laws; prohibiting prior authorization for oral and inhaled generic prescription drugs; prohibiting prior authorization for inhaled prescription drugs for asthma, chronic obstructive pulmonary disease, or chronic lung disease; prohibiting prior authorization for insulin; requiring insurers to provide a list of reasonable therapeutic alternatives if the insurer makes an adverse determination for a prescription drug; and amending section 33-32-221, mca.
- What is the status of HB399?
- Signed into law as of April 17, 2025. Latest action: Chapter Number Assigned (April 17, 2025).
- Who sponsored HB399?
- Karlen, Jonathan (D, 98), with 1 co-sponsor.
- Where is the official record for HB399?
- On the Montana Legislature website: https://bills.legmt.gov/#/laws/bill/2/LC1957
Source: official Montana record. Tracked by Delilah, AI for legislation across all 50 states and Congress.